CTOs on the Move

Visus Therapeutics

www.visustx.com

 
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOLâ„¢), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.visustx.com
  • 2 Nickerson Street Suite 101
    Seattle, WA USA 98109
  • Phone: 800.281.4536

Executives

Name Title Contact Details

Funding

Visus Therapeutics raised $36M on 03/09/2021

Similar Companies

Inversago Pharma

A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).

Merrimack

At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.

Algenix

Algenix is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inizio

Inizio is a strategic partner for health and life sciences with a full suite of medical, marketing, advisory and engagement services throughout the drug lifecycle.

CDx Diagnostics

The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.